Insulin treatment is the choice in insulinopenic diabetic patients, in order to prevent or delay microvascular lesions, related to hyperglycaemia. However in insulin resistant type 2 diabetes, the improvement in glycaemic control with insulin, is not without side effects, especially weight gain and hypoglycaemia. Many retrospective or case-control studies of insulin treatment have reported a higher prevalence of CVD in insulin-treated patients. However, many of these patients started insulin therapy in relation to different clinical settings, following this treatment for years. In clinical practice, the physician needs a protocol to assess the possible withdrawal of insulin in some of them.
Why consider withdrawal of insulin in insulin resistent, T2DM
The load of cardiovascular risk factors (CVRFs) includes hypertension, dyslipidaemia (reduced HDL-cholesterol, elevated triglycerides, and small dense LDL particles), obesity (especially visceral), physical inactivity, sub-clinical inflammation, and endothelial dysfunction. This cluster, referred to as metabolic or insulin resistance syndrome, consistently predicts atherosclerotic CVD (ATCVD) [5] . Many studies have reported an association between insulin resistance/hyperinsulinaemia and ATCVD in the general population [6] [7] [8] . Moreover, in cross-sectional analyses insulin treatment in T2DM patients is consistently associated with the presence of atherosclerotic CVD (ATCVD) even after adjusting for multiple CVRFs [9] . However, in most studies insulin resistance was not measured directly and control for statistical confounding was incomplete. Thus, in a cohort of carefully phenotyped non-diabetic subjects baseline insulin resistance (as measured by the euglycaemic insulin clamp technique) was independently associated with a small increment in the intima-media thickness of the common carotid artery (carotid intima-media thickness, C-IMT) -an antecedent of CVD [10].
In examining the effect of currently approved glucose-lowering drugs on established CVRFs and, where available, on CV mortality and morbidity, two preliminary considerations are important. First, micro and macrovascular T2DM complications often coexist in the same patient but have partially different pathophysiology and risk factors. Also, the dose-response relation of hyperglycaemia to microvascular complications is significantly steeper than to macrovascular disease [11, 12] . Secondly, the vast majority of epidemiologic studies and clinical trials is based on major adverse cardiac events (MACE) as
Introduction
Type 2 diabetes (T2DM) is a chronic and progressive process consists of a group of diseases that are characterized by increased plasma glucose concentration as a result of both, changes in the function of the beta and alpha islet pancreatic cells, and different degrees of insulin resistance (IR), which usually behave compensatory hyperinsulinaemia (HI) in relation to the degree of IR [1] . In clinical practice the patient phenotyping is essential to choose the most appropriate treatment, in relation to the underlying pathophysiological alteration, so if beta-cell failure is the principal cause, the patient is usually in normal weight or in progressive weight reduction. In these cases, the use of insulin is the choice in order to normalize blood glucose level. However, approximately 80-90% of patients are usually overweight or obese. In these cases, the predominant underlying pathophysiological mechanism was IR/HI. It is conclusively established that the microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) are directly related to the severity and duration of hyperglycaemia, as reflected by the HbA1c [2,3]. However, macrovascular complications are the primary cause of mortality, with myocardial infarction (MI) and stroke accounting for 80% of all deaths in T2DM patients [4] .
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Nubiola et al. Int J Diabetes Clin Res 2015, 2:6 normalize HbA1c in virtually all T2DM patients. However, the improvement in glycaemic control is not without side effects, especially weight gain and hypoglycaemia [14] .
Many retrospective or case-control studies of insulin treatment have reported a higher prevalence of CVD in insulin-treated patients [15] [16] [17] [18] [19] [20] . The opposite indication from epidemiological studies and randomized controlled trials remains problematic. The biology of insulin's action on the vasculature is ambivalent. In fact, insulin can promote atherogenesis through several mechanisms. From the clinical standpoint, it is reasonable to assume that in T2DM patients, the positive association between the pharmacological use of insulin and ATCVD may be explained by the cross-sectional, retrospective nature of many studies, [21, 17] and by a strong indication bias (e.g., insulin is most often used in long-standing, complicated diabetes). Hypoglycaemia also occurred frequently in ORIGIN (42 and 14% of patients in the glargine and standard therapy groups, respectively); severe hypoglycaemia was associated with a greater risk for allcause mortality, CV death, and arrhythmic death [22] . Finally, the possibility that high doses of insulin (> 80-100 units/day) in insulin resistant T2DM patients may accelerate the progression of vascular damage cannot be conclusively ruled out [23] . Hyperglycaemia/ insulin resistance control should take place within a comprehensive approach in order to reduce cardiovascular risk. Because T2DM is associated with a markedly increased incidence of cardiovascular complications, it is advantageous that the medications used to restore normoglycaemia not aggravate known cardiovascular risk factors (CVRFs), not accelerate the underlying atherogenic process and, optimally, reduce cardiovascular risk.
However, many of these patients started insulin therapy in relation to different clinical settings, when the patient is unable to make changes in your lifestyle or related to glucocorticoid therapy, or after hospitalization, surgery, among others, following this treatment for years. In clinical practice, the physician needs a protocol to assess the possible withdrawal of insulin in some of them. On the other hand, there are numerous studies linking HI with cancer risk [24] [25] [26] [27] [28] [29] [30] . Other reasons for the possible withdrawal of insulin are evident in table 1.
When you consider withdrawal of insulin in insulin resistant, T2DM
T2DM, obese insulin treated patients, with the characteristics described above, without clinical insulinopenia criteria when start this treatment (weight reduction), with a correct C -peptide reserve. (C-peptide levels in the morning after having insulin dose by night, can help us) [31] .
How consider withdrawal of insulin in insulin resistant, T2DM
Bibliographic data related to a protocol for a possible withdrawal of insulin are surprisingly rare if we consider the frequency of these patients in our clinical practice.
The references we could find back to more than twenty years ago [32] [33] [34] [35] [36] . Some studies in bariatric surgery and T2DM, a vague reference to the fact that in some cases, insulin treatment is suppressed after surgery is done, but no protocol specified how. No data are found in this regard, positioning, consensus of the different scientific diabetes societies recommendations. For this reason, it is difficult to choose criteria of evidence-based medicine, so we propose a protocol developed based on logic and experience care, often low considered, to shed some light on this issue (Table 2) .
Conclusion
In different clinical situations, we started insulin therapy in obese patients with T2DM. However, in many cases we can rethink the need to continue this treatment when the patient's condition has changed. However, most clinical guidelines is not explained how. The manuscript is intended to bring some light on this subject.
Just as premature started insulin treatment in T2DM patients with clinical and metabolic criteria of insulinopenia, in order to prevent or delay microvascular lesions related to hyperglycemia, it should also arise in some cases possible removal of insulin treatment in diabetic insulin resistant patients, in order to prevent or delay cardiovascular risk, minimizing hypoglycaemia and excessive weight gain.
It's not intention of the authors indiscriminately removing insulin to patients with T2DM. We provide a protocol to help clinician to try it in patients with features described, since virtually no literature on it. We hope thereby sensitize the various scientific societies in the field of diabetes to develop a protocol agreed in this regard. 
